FGEN - FibroGen, Inc.
50.67 0.00 (0.00%)
After hours: 5:02PM EST
| Previous Close | 49.11 |
| Open | 49.22 |
| Bid | 50.25 x 900 |
| Ask | 62.00 x 1300 |
| Day's Range | 49.22 - 50.80 |
| 52 Week Range | 37.27 - 68.55 |
| Volume | 590,609 |
| Avg. Volume | 695,253 |
| Market Cap | 4.306B |
| Beta (3Y Monthly) | 2.67 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.76 |
| Earnings Date | Feb 25, 2019 - Mar 1, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 71.00 |
- Markit•8 days ago
See what the IHS Markit Score report has to say about FibroGen Inc.
# FibroGen Inc ### NASDAQ/NGS:FGEN View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding FGEN is favorable, with net inflows of $5.19 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Investor's Business Daily•27 days ago
Can This Biotech Stock Rival Amgen In Anemia? Analyst Says Yes
Fibrogen stock popped Thursday on results of clinical studies showing that its AstraZeneca-partnered anemia treatment in kidney disease patients could rival Amgen's.
- The Wall Street Journal•27 days ago
[$$] Big Pharma Wins Drug Approval in China Ahead of West for First Time
China has for the first time approved a treatment from a global drugmaker before any other country, illustrating its recent push to bring in cutting-edge medicines—as well as Western companies’ growing interest in the market. China approved 30 innovative drugs from foreign developers in the first nine months of this year—some taking just weeks—and, according to consulting firm McKinsey & Co., is on track to at least match last year’s 40 approvals, which marked the most by the regulator in any single year for at least a decade. In 2016, China approved three such foreign drugs.
- MarketWatch•27 days ago
AstraZeneca stock up 2.8% after announcing EU approval of COPD treatment
Shares of AstraZeneca Plc were up 2.8% in premarket trade Thursday after the company announced its inhaler Bevespi Aerosphere was approved by the European Commission as a treatment for symptoms of chronic obstructive pulmonary disease (COPD). The inhaler is already available to COPD patients in the U.S. Earlier on Thursday, the company announced that two major Phase 3 trials of roxadustat, a potential treatment for anemic patients with chronic kidney disease being developed with FibroGen, Inc. , had met their primary endpoints. Shares of AstroZeneca have gained 18% in the year to date, while the S&P 500 has fallen 6%.
- Markit•28 days ago
See what the IHS Markit Score report has to say about FibroGen Inc.
# FibroGen Inc ### NASDAQ/NGS:FGEN View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Positive Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding FGEN are favorable, with net inflows of $1.79 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- GlobeNewswire•28 days ago
FibroGen Announces Positive Topline Results from Three Global Phase 3 Trials of Roxadustat for Treatment of Anemia in Patients with Chronic Kidney Disease
FibroGen, Inc. (FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today announced that roxadustat, an inhibitor of hypoxia-inducible-factor (HIF) prolyl hydroxylase activity (HIF-PHI), met all primary efficacy endpoints in the three global pivotal Phase 3 trials conducted by FibroGen: ANDES in non-dialysis-dependent (NDD) chronic kidney disease (CKD) patients, HIMALAYAS in incident (newly initiated) dialysis patients, and SIERRAS in dialysis-dependent (DD) CKD patients. “Anemia in CKD is a serious condition for which a significant number of patients are left without treatment options in many markets,” said Thomas B. Neff, Chief Executive Officer, FibroGen.
- ACCESSWIRE•28 days ago
Today's Research Reports on Trending Tickers: Aimmune Therapeutics and FibroGen
NEW YORK, NY / ACCESSWIRE / December 20, 2018 / U.S. equities closed down on Wednesday as the anticipated interest rate increase was confirmed by the Federal Reserve, following Chairman Jerome Powell’s ...
- Insider Monkey•29 days ago
FibroGen Inc (FGEN): Hedge Fund Sentiment Unchanged
Before we spend days researching a stock idea we’d like to take a look at how hedge funds and billionaire investors recently traded that stock. S&P 500 Index ETF (SPY) lost 8.7% through October 26th. Forty percent of the S&P 500 constituents were down more than 10%. The average return of a randomly picked stock […]
- American City Business Journals•29 days ago
Why a kidney disease drug approval in China is just the start for this S.F. company
After 25 years, FibroGen won its first drug approval, a treatment for anemia in chronic kidney disease patients in China. It hopes to follow that up with approvals in the United States, Japan and Europe over the next year.
- Benzinga•last month
The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 17) Endocyte, Inc. (NASDAQ: ECYT ) Down In The Dumps (Biotech ...
- ACCESSWIRE•last month
Today's Research Reports on Trending Tickers: Puma Biotechnology and FibroGen
NEW YORK, NY / ACCESSWIRE / December 18, 2018 / U.S. equities extended losses on Monday as investors await details from the Federal Reserve's final policy meeting of 2018 on Wednesday. The Dow Jones Industrial ...
- Reuters•last month
China first to approve AstraZeneca, FibroGen anaemia drug
China has become the first country to approve a new anaemia drug from AstraZeneca and FibroGen, well before decisions by regulators in the United States or Europe. Despite the early win, the two partners said on Tuesday they did not expect to launch roxadustat in China until the second half of 2019. FibroGen sponsored the development and registration of roxadustat in China, while AstraZeneca is responsible for marketing the medicine.
- Reuters•last month
China first to approve AstraZeneca, FibroGen anaemia drug
China has become the first country to approve a new anaemia drug from AstraZeneca and FibroGen, well before decisions by regulators in the United States or Europe. Despite the early win, the two partners said on Tuesday they did not expect to launch roxadustat in China until the second half of 2019. FibroGen sponsored the development and registration of roxadustat in China, while AstraZeneca is responsible for marketing the medicine.
- GlobeNewswire•last month
FibroGen Announces Approval of Roxadustat in China for the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis
FibroGen, Inc. (FGEN) today announced that FibroGen (China) Medical Technology Development Co., Ltd. (FibroGen China) has received marketing authorization from the National Medical Products Administration (NMPA) for roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the treatment of patients with anemia caused by chronic kidney disease (CKD) in patients who are dialysis-dependent (DD). The medicine can be prescribed to patients who use hemodialysis or peritoneal dialysis.
- Simply Wall St.•last month
How Many Insiders Sold FibroGen, Inc. (NASDAQ:FGEN) Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that there are more than a few examples Read More...
Markit•last monthSee what the IHS Markit Score report has to say about FibroGen Inc.
FibroGen Inc NASDAQ/NGS:FGEN
- GlobeNewswire•last month
FibroGen Appoints Maykin Ho, Ph.D., to Board of Directors
“We are delighted to welcome Dr. Maykin Ho, an accomplished leader with a great breadth of knowledge in the biotechnology industry, as a new Board member,” said Thomas B. Neff, CEO. Dr. Ho has more than 30 years of experience in the healthcare and finance industries.
- GlobeNewswire•2 months ago
New Research Coverage Highlights Phibro Animal Health, RadNet, Amphastar Pharmaceuticals, FibroGen, Sientra, and Flexion Therapeutics — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Markit•2 months agoSee what the IHS Markit Score report has to say about FibroGen Inc.
Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The net inflows of $227 million over the last one-month into ETFs that hold FGEN are among the lowest of the last year and appear to be slowing.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of FGEN earnings conference call or presentation 8-Nov-18 10:00pm GMT
Q3 2018 FibroGen Inc Earnings Call
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: Amicus Therapeutics and FibroGen
NEW YORK, NY / ACCESSWIRE / November 14, 2018 / U.S. equities saw losses on Tuesday as continued weakness in oil prices pressured energy stocks lower. Crude oil dropped for the 12th consecutive session, ...
Markit•2 months agoSee what the IHS Markit Score report has to say about FibroGen Inc.
Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold FGEN had net inflows of $1.75 billion over the last one-month.
- Zacks•2 months ago
FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates
FibroGen (FGEN) delivered earnings and revenue surprises of -42.86% and -37.04%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
FibroGen: 3Q Earnings Snapshot
The San Francisco-based company said it had a loss of 50 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•2 months ago
FibroGen Reports Third Quarter 2018 Financial Results
—Roxadustat New Drug Applications under Review in China and Japan——Phase 3 Clinical Trials in IPF and Pancreatic Cancer to Initiate in First Quarter 2019——Conference Call Today.
